12:53 AM EDT, 09/29/2026 (MT Newswires) -- Egetis Therapeutics (EGTX.ST) secured the US Food and Drug Administration's approval for Emcitate to treat peripheral thyrotoxicosis in adults and children with monocarboxylate transporter 8 deficiency. The pharmaceutical company said Monday that it supported its application with results from a comprehensive clinical development program that included the ReTRIACt, Triac Trial I, Triac Trial II, Erasmus Medical Center cohort study, EMC survival study and the US Expanded Access Program. Egetis expects the US commercial launch of Emcitate, or tiratricol, in the next eight to 10 weeks after approval.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.